+++
title = "Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke."
date = "2017-09-01"
authors = ["Mas Jean-Louis", "Derumeaux Genevieve", "Guillon Benoit", "Massardier Evelyne", "Hosseini Hassan", "Mechtouff Laura", "Arquizan Caroline", "Bejot Yannick", "Vuillier Fabrice", "Detante Olivier", "Guidoux Celine", "Canaple Sandrine", "Vaduva Claudia", "Dequatre-Ponchelle Nelly", "Sibon Igor", "Garnier Pierre", "Ferrier Anna", "Timsit Serge", "Robinet-Borgomano Emmanuelle", "Sablot Denis", "Lacour Jean-Christophe", "Zuber Mathieu", "Favrole Pascal", "Pinel Jean-Francois", "Apoil Marion", "Reiner Peggy", "Lefebvre Catherine", "Guerin Patrice", "Piot Christophe", "Rossi Roland", "Dubois-Rande Jean-Luc", "Eicher Jean-Christophe", "Meneveau Nicolas", "Lusson Jean-Rene", "Bertrand Bernard", "Schleich Jean-Marc", "Godart Francois", "Thambo Jean-Benoit", "Leborgne Laurent", "Michel Patrik", "Pierard Luc", "Turc Guillaume", "Barthelet Martine", "Charles-Nelson Anais", "Weimar Christian", "Moulin Thierry", "Juliard Jean-Michel", "Chatellier Gilles", "Domigo V", "Guiraud V", "Touze E", "Calvet D", "Lamy C", "Teiger E", "Dubois-Rande J-L", "Aubry P", "Varenne O", "Menacer S", "Sroussi M", "Nana A", "Cabanes L", "Schunck A", "Herisson F", "De Gaalon S", "Sevin M", "Langlard J-M", "Piriou N", "Jaafar P", "d'Here B", "Stepowski D", "Bauer F", "Duval A-M", "Lim P", "Nighoghossian N", "Derex L", "Cho T", "Rioufol G", "Thibaut H", "Thivolet S", "Mourand I", "Sportouch C", "Cade S", "Cransac F", "Giroud M", "L'Huillier I", "Chopard R", "Descotes-Genon V", "Garambois K", "Saunier C", "Brochet E", "Mazighi M", "Meseguer E", "Messika-Zeitoun D", "Cabrejo L", "Lavallee P", "Lepage L", "Amarenco P", "Bugnicourt J-M", "Godefroy O", "Rey C", "Guillaumont M-P", "Trojette F", "Malaquin D", "Couvreur G", "Golfier V", "Plurien F", "Taldir G", "Lucas C", "Cordonnier C", "Henon H", "Dumont F", "Leys D", "Richardson M", "Polge A-S", "Montaigne D", "Coisne A", "Rouanet F", "Renou P", "Reant P", "Laffite S", "Roudaut R", "Comtet C", "Delsart D", "Bourgois N", "Clavelou P", "Rouhart F", "Le Cadet E", "Tirel A", "Mocquard Y", "Jobic Y", "Le Ven F", "Pouliquen M-C", "Milandre L", "Laksiri N", "Fraisse A", "Habib G", "Chalvignac V", "Thuny F", "Targosz F", "Runavot G", "Chopat P", "Sultan P", "Richard S", "Ducrocq X", "Marcon F", "Selton-Suty M C", "Huttin O", "Bruandet M", "Tamazyan R", "Antakly Y", "Garcon P", "Serfaty J", "Hammoudi N", "Donal E", "Lelong B", "Chabanne C", "Viader F", "Cogez J", "Labombarda F", "Saloux E", "Buffon F", "Baudet M", "Logeart D", "Bataille M", "Godard F", "Biausque F", "Lefetz Y", "Clement-Dupont M", "Zegarac V", "Schmitz T", "Plicht B", "Eissmann M", "Mahabadi A", "Obadia M", "Iglesias Benyounes N", "Macian F", "Darodes N", "Tanguy B", "Mohty D", "Vuillemet F", "Onea R", "Greciano S", "Roth O", "Neau J-P", "Quillet L", "Christiaens L", "Saudeau D", "Patat F", "Singer O", "Fichtlscherer S", "Pico F", "Charbonnel C", "Durand-Zaleski I", "Woimant F", "Finet G", "Mounier-Vehier F", "Rodier G", "Ernande L", "Lievre M", "Andrieux Chantal", "Sauret Isabelle", "Bruyere Clemence", "Chenu Romain", "Trinquart Ludovic", "Alsaleh Khaled", "Bousry Djennat", "Branco Sonia", "Brussieux Maxime", "Greaud Cecile", "Kacher Zineb", "Loret Laurie", "Niranjani Mahendran", "Olivier Audrey", "Pigeat Romain", "Sahuc Karen", "Djadi-Prat Juliette"]
publication_types = ["2"]
publication = "The New England journal of medicine, https://doi.org/10.1056/NEJMoa1705915"
publication_short = "The New England journal of medicine, https://doi.org/10.1056/NEJMoa1705915"
abstract = "BACKGROUND:Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.METHODS:In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3.RESULTS:A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 238 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet-only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P&lt;0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P=0.02). The number of serious adverse events did not differ significantly between the treatment groups (P=0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone.CONCLUSIONS:Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289 .). "
abstract_short = ""
image_preview = ""
selected = false
projects = []
tags = []
url_pdf = ""
url_preprint = ""
url_code = ""
url_dataset = ""
url_project = ""
url_slides = ""
url_video = ""
url_poster = ""
url_source = ""
math = true
highlight = true
[header]
image = ""
caption = ""
+++
<a href="https://www.scimagojr.com/journalsearch.php?q=15847&amp;tip=sid&amp;exact=no" title="SCImago Journal &amp; Country Rank"><img border="0" src="https://www.scimagojr.com/journal_img.php?id=15847" alt="SCImago Journal &amp; Country Rank"  /></a>
**SCImago Journal Rank (SJR)** est un indicateur de notoriété des revues indexées à partir de 1996 dans la base de données Scopus de l’éditeur Elsevier. Le SJR a été créé par le groupe de travail SCImago Research Group (SRG) de l’Université de Grenade et Alcana de Henares en Espagne.  
  
Le SJR d’une revue est le nombre de fois où un article de cette revue est cité par d’autres articles pendant les 3 ans qui suivent sa publication, chaque citation reçue étant pondérée par la notoriété de la revue citante. Les articles « citants » sont issus d’autres revues et de la revue notée. Les citations d’articles de la revue par des articles de cette même revue (on parle d’autocitations) sont ainsi incluses dans le calcul du SJR, mais dans une limite de 35 %. Dans le calcul du SJR, le nombre de citations reçues par une revue est rapporté au nombre d’articles publiés par la revue au cours des 3 années qui précèdent.  
  
L'ensemble des revues a été classé en fonction de leur SJR et divisé en quatre groupes égaux, quartiles. Q1 (vert) comprend le quart des journaux avec les valeurs les plus élevées, Q2 (jaune) les deuxièmes valeurs les plus élevées, Q3 (orange) les troisièmes valeurs les plus élevées et Q4 (rouge) les valeurs les plus faibles.  
  
Différent entre le **SJR** et l'**Impact Factor** :  
- Le SJR est calculé pour une période de citation de 3 ans. Il tient compte de la notoriété des revues citantes. Il inclut de façon limitée les autocitations d’une revue ;  
- L'Impact Factor est calculé pour une période de citation de 2 ans. Il ne tient pas compte de la notoriété des revues citantes. Il inclut toutes les autocitations d’une revue.
